Literature DB >> 11939269

Successful treatment of nasal T-cell lymphoma with a combination of local irradiation and high-dose chemotherapy.

Takaomi Sanda1, Shinsuke Lida, Masato Ito, Kazuya Tsuboi, Kazuhisa Miura, Shinsuke Harada, Hirokazu Komatsu, Atsushi Wakita, Hiroshi Inagaki, Ryuzo Ueda.   

Abstract

Nasal natural killer (NK)/T-cell lymphoma is characterized by an aggressive clinical course and poor prognosis. The term "NK/T-cell" lymphoma includes both the NK-cell type and the T-cell type, which are classified by immunophenotyping and according to T-cell receptor (TCR) rearrangement. In addition, CD56+ T-cell lymphoma is defined as NK-like T-cell lymphoma. This report concerns a 54-year-old woman with nasal T-cell lymphoma. Its phenotype showed pure T-cell type with CD3+, CD56-, and TCR+ accompanied by Epstein-Barr virus infection. Although the lesions were localized in the nasal mucosa and facial skin (stage IE), local irradiation could not achieve complete remission (CR). We then administered 5 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen followed by high-dose chemotherapy with an autologous peripheral blood stem cell transplantation. This therapy resulted in CR. Our results suggest that this lymphoma subtype may be cured by means of intensive treatment soon after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939269     DOI: 10.1007/BF02982028

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

Review 1.  Autologous bone marrow transplantation for patients with aggressive non-Hodgkin's lymphoma.

Authors:  J O Armitage
Journal:  Bone Marrow Transplant       Date:  1992       Impact factor: 5.483

2.  Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.

Authors:  A Nademanee; A Molina; M R O'Donnell; A Dagis; D S Snyder; P Parker; A Stein; E Smith; I Planás; A Kashyap; R Spielberger; H Fung; K K Wong; G Somlo; K Margolin; W Chow; I Sniecinski; N Vora; K G Blume; J Niland; S J Forman
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

3.  Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma.

Authors:  R Liang; F Chen; C K Lee; Y L Kwong; C S Chim; C C Yau; E Chiu
Journal:  Bone Marrow Transplant       Date:  1997-01       Impact factor: 5.483

4.  Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage.

Authors:  A K Chiang; A C Chan; G Srivastava; F C Ho
Journal:  Int J Cancer       Date:  1997-11-04       Impact factor: 7.396

5.  Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients, retrospective study covering an eight-year period.

Authors:  F C Ho; D Todd; S L Loke; R P Ng; R K Khoo
Journal:  Int J Cancer       Date:  1984-08-15       Impact factor: 7.396

6.  Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies.

Authors:  Y Harabuchi; S Imai; J Wakashima; M Hirao; A Kataura; T Osato; S Kon
Journal:  Cancer       Date:  1996-05-15       Impact factor: 6.860

7.  Epstein-Barr virus in patients with polymorphic reticulosis (lethal midline granuloma) from China and Japan.

Authors:  K Mishima; K Horiuchi; S Kojya; H Takahashi; M Ohsawa; K Aozasa
Journal:  Cancer       Date:  1994-06-15       Impact factor: 6.860

8.  Association of Epstein-Barr virus with sinonasal angiocentric T cell lymphoma.

Authors:  G O'Leary; S M Kennedy
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

Review 9.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

10.  Treatment outcome and prognostic factors for primary nasal lymphoma.

Authors:  R Liang; D Todd; T K Chan; E Chiu; A Lie; Y L Kwong; D Choy; F C Ho
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

View more
  1 in total

Review 1.  Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia.

Authors:  Yok-Lam Kwong
Journal:  Int J Hematol       Date:  2010-11-25       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.